<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04133844</url>
  </required_header>
  <id_info>
    <org_study_id>35RC19_9727_ATECMO</org_study_id>
    <nct_id>NCT04133844</nct_id>
  </id_info>
  <brief_title>Evaluation of Antithrombin Deficiency in Patients of Intensive Care Unit Placed on Extracorporeal Membrane Oxygenation</brief_title>
  <acronym>ATECMO</acronym>
  <official_title>Evaluation of Antithrombin Deficiency in Patients of Intensive Care Unit Placed on Extracorporeal Membrane Oxygenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, monocentric, non-interventional study in patients placed on extracorporeal
      membrane oxygenation (ECMO)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our hypothesis is that ECMO initiation is responsible for a severe decrease of antithrombin
      level in a high proportion of patients who develop heparin resistance.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To study antithrombin level from during the first 24h after ECMO initiation</measure>
    <time_frame>Day 7</time_frame>
    <description>Blood sample at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study antithrombin level 24h after initialization of ECMO</measure>
    <time_frame>Hour 24</time_frame>
    <description>Blood sample at 24h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the prevalence of antithrombin (AT) deficiency (â‰¤70%) at each time point (from H0 to day 7)</measure>
    <time_frame>Day 7</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study relationship between antithrombin level and heparin resistance</measure>
    <time_frame>Day 7</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study relationship between antithrombin level and thrombin generation test</measure>
    <time_frame>Day 7</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study clinical factors associated with AT deficiency</measure>
    <time_frame>Day 7</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe clinical evolution of patients according to initial AT level</measure>
    <time_frame>Hour 0</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Severe Cardiac Insufficiency</condition>
  <arm_group>
    <arm_group_label>Extracorporeal membrane oxygenation</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood sample collection from a peripheral catheter at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation</description>
    <arm_group_label>Extracorporeal membrane oxygenation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with cardiac insifficiency placed on extracorporeal membrane oxygenation (ECMO)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any ICU patient of receiving veno-arterial extracorporeal membrane oxygenation

          -  Patients who have not expressed opposition to participate

        Exclusion Criteria:

          -  Arterial thrombosis or progressive venous thrombosis

          -  Contraindication to heparin

          -  Constitutional deficiency in antithrombin

          -  Patient refusal

          -  Minor patient

          -  Protected major (safeguard justice, trusteeship and guardianship) and persons deprived
             of liberty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Isabelle Gouin-Thibault, MD</last_name>
    <phone>02.99.28.95.63</phone>
    <email>isabelle.gouin@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandre Mansour, Intern</last_name>
    <phone>06.47.53.34.16</phone>
    <email>alexandre.mansour@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle Gouin-Thibault, MD</last_name>
      <phone>02.99.28.95.63</phone>
      <email>isabelle.gouin@chu-rennes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexandre Mansour, Intern</last_name>
      <phone>06.47.53.34.16</phone>
      <email>alexandre.mansour@chu-rennes.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2019</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>extracorporeal membrane oxygenation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Antithrombin III Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

